Latest News and Press Releases
Want to stay updated on the latest news?
-
ATLANTA, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Antios Therapeutics, Inc. (“Antios”) today announced the appointment of seasoned financial executive, Tamra J. Adams, as the Company’s chief financial...
-
AUSTIN, Texas, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Bumble Inc. announced today that it has closed its initial public offering of 57,500,000 shares of its Class A common stock at a price to the public...
-
New York, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Grayscale Investments®, the world’s largest digital currency asset manager, today announced the official appointment of three new C-suite hires: Hugh...
-
Hamilton, Bermuda, Feb. 16, 2021 (GLOBE NEWSWIRE) -- (via Blockchain Wire) Asset management firms Alpha Innovations (“AI”) and Arcanum Capital (“Arcanum”) today announced the launch of the Arcanum...
-
BRYAN, Texas, Feb. 16, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the...
-
NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) announced today the pricing of $50 million in aggregate principal amount of...
-
TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the...
-
加州三藩市, Feb. 12, 2021 (GLOBE NEWSWIRE) -- 天演藥業 (Adagene Inc.)(以下簡稱「天演藥業」或「公司」)(納斯達克股票代碼:ADAG),是一家平台驅動、致力創新抗體技術癌症免疫療法發現和開發的臨床階段生物製藥企業,今天宣佈完成 8,457,100 美國存託股票(「ADS」)的首次公開發行(「IPO」),其中包括行使承銷商的超額配股權的...
-
PALO ALTO, Calif. , Feb. 12, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of a secondary public offering of...
-
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. FOR...